Relationship Between the National Institutes of Health Chronic Prostatitis Symptom Index and the International Prostate Symptom Score in Middle-Aged Men According to the Presence of Chronic Prostatitis-Like Symptoms NIH-CPSI pain score correlates with IPSS score

Main Article Content

Min Ho Lee http://orcid.org/0000-0001-8938-145X
Deok Ha Seo
Chunwoo Lee
Jae Hwi Choi
Sin Woo Lee
Seong Uk Jeh
See Min Choi
Jeong Seok Hwa
Jae Seog Hyun
Ky Hyun Chung
Sung Chul Kam

Keywords

Prostatitis, Lower Urinary Tract Symptoms, Questionnaires, Prostatic Hyperplasia

Abstract

Background and objective
The characteristic symptom of chronic prostatitis (CP) is pain. Patients with CP often complain of lower urinary tract symptoms (LUTS); however, the voiding domain of the Chronic Prostatitis Symptom Index of the National Institutes of Health (NIH-CPSI) is not sufficient to evaluate LUTS. Therefore, we studied the relationship between the International Prostate Symptom Score (IPSS) and NIH-CPSI scores in men.


Materials and methods
We reviewed 870 men who visited our health care center for a general health check-up and com-pleted IPSS and NIH-CPSI questionnaires between January 2014 and January 2019. An NIH-CPSI pain score ≥4 was defined as the presence of a prostatitis-like symptom (Group 1), and an NIH-CPSI pain score less than <4 was defined as the absence of a prostatitis-like symptom (Group 2). The relationship between IPSS and NIH-CPSI sub-scores was investigated. The associations between the IPSS total score and NIH-CPSI sub-scores were assessed using multiple linear regres-sion analysis.


Results
The mean IPSS total, voiding, storage, and quality-of-life (QOL) scores were higher in Group 1 than in Group 2. Group 1 had fewer subjects in the mild group and more in the moderate and severe groups than did Group 2. Among NIH-CPSI sub-scores, pain score showed the highest correlation between IPSS total (r=0.283), voiding (r=0.266), storage (r=0.237), and QOL score (r=0.263). In regression analysis, only the NIH-CPSI pain score was associated with the IPSS total score (B=0.962, p<0.001). Conclusions
The NIH-CPSI pain score showed a weak but statistically significant correlation with the IPSS, but the NIH-CPSI voiding score did not. This finding suggests that patients with CP-like symptoms need to be surveyed using the IPSS questionnaire. It will also be helpful to screen for comorbidities of benign prostatic hyperplasia and CP.

Downloads

Download data is not yet available.
Abstract 42 | PDF Downloads 30 HTML Downloads 6 XML Downloads 0

References

1. Ezeanyika LU, Ejike CE, Obidoa O, et al. Prostate disorders in an apparently normal Nigerian population: prevalence. Biokemistri 2006;18(2): 127–32.
2. Zhang SJ, Qian HN, Zhao Y, et al. Relationship between age and prostate size. Asian J Androl 2013;15(1):116–20.
3. Eze BU, Mbaeri TU, Oranusi KC, et al. Correlation between intravesical prostatic protrusion and International Prostate Symptom Score among Nigerian men with benign prostatic hyperplasia. Niger J Clin Pract 2019;22(4):454–9.
4. Barry MJ. Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia. Urology 2001;58(Suppl 6):25–32.
5. Barry MJ, Fowler FJ Jr, O’Leary MP, et al. The  American Urological Association symp-tom index for benign prostatic hyperplasia. The measurement committee of the American Urological Association. Urology 1992;148(5): 1549–64.
6. Mizuno T, Hiramatsu I, Aoki Y, et al. Relation between histological prostatitis and lower urinary tract symptoms and erectile function. Prostate Int 2017;5(3):119–23.
7. Krieger JN, Nyberg Jr L, Nickel JC. NIH consen-sus definition and classification of prostatitis. JAMA 1999;282(3):236–7.
8. Woo YN. Prostatitis. Korean J Urol 1999;35(6): 575–85.
9. Litwin M, McNaughton-Collins M, Fowler FJ, et al. The National Institutes of Health Chronic Prostatitis Symptom Index: development and val-idation of a new outcome measure. J Urol 1999; 162(2):369–75.
10. Nickel JC, Downey J, Hunter D, et al. Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J Urol 2001;165(3): 842–5.
11. Liang CZ, Zhang XJ, Hao ZY, et al. An epidemi-ological study of patients with chronic prostatitis. BJU Int 2004;94(4):568–70.
12. Tran CN, Shoskes DA. Sexual dysfunction in chronic prostatitis/chronic pelvic pain syndrome. World J Urol 2013;31(4):741–6.
13. Zhang Y, Zheng T, Tu X’an, et al. Erectile dys-function in chronic prostatitis/chronic pelvic pain syndrome: outcomes from a multi-center study and risk factor analysis in a single center. PLoS One 2016;11(4):e0153054.
14. Li HJ, Kamg DY. Prevalence of sexual dysfunc-tion in men with chronic prostatitis/ chronic pel-vic pain syndrome: a meta-analysis. World J Urol 2016;34(7):1009–17.
15. Zhang Z, Li Z, Yu Q, et al. The prevalence of and risk factors for prostatitis-like symptoms and its relation to erectile dysfunction in Chinese men. Andrology 2015;3(6):1119–24.
16. Rubinshtein R, Kuvin JT, Soffler M, et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse event. Eur Heart J 2010;31(9):1142–8.
17. Nickel JC, Tripp DA, Chuai S, et al. Psychosocial variables affect the quality of life of men diag-nosed with chronic prostatitis/chronic pelvic pain syndrome. BJU Int 2008;101(1):59–64.
18. Cho IC, Kim SB, Kim YS, et al. Analysis of cor-relation between The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) and International Index of Erectile Function (IIEF-5) among Korean males aged 40–50s. Korean J UTII 2012;7(2):164–71.
19. Marszalek M, Wehrberger C, Temml C, et al. Chronic pelvic pain and lower urinary tract symp-toms in both sexes: analysis of 2749 participants of an urban health screening project. Eur Urol 2009;55(2):499–507.
20. Urkmez A, Yuksel OH, Uruc F, et al. The effect of asymptomatic histological prostatitis on sexual function and lower urinary tract symptoms. Arch Esp Urol 2016;69(4):185–91.
21. Robert G, Descazeaud A, Nicolaiew N, et al. Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate 2009;69(16):1774–80.
22. Gandaglia G, Briganti A, Gontero P, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign pros-tatic hyperplasia (BPH). BJU Int 2013;112(4): 432–41.
23. Nickel JC, Roehrborn CG, O’Leary MP, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 2008;54(6):1379–84.